Previous studies have shown that high levels of TIGAR expression are closely associated with poor clinical outcomes in patients with multiple types of cancer including chronic lymphocytic leukemia (Hong et al., 2016), invasive breast cancer (Won et al., 2012), Stages II and III colorectal cancer (Alkhayal et al., 2016), nasopharyngeal carcinoma (Wong et al., 2015; Zhao et al., 2016), and non‐small‐cell lung cancer (Shen et al., 2018). This evidence concerns the gene TIGAR and cancer.